| Current Price | $18.12 | Mkt Cap | $5.7B |
|---|---|---|---|
| Open | $17.73 | P/E Ratio | 34.54 |
| Prev. Close | $18.12 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.53 - $18.12 | Volume | 1,707,535 |
| 52-Wk Range | $15.50 - $25.77 | Avg. Daily Vol. | 1,908,552 |
A development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
| Current Price | $18.12 | Mkt Cap | $5.7B |
|---|---|---|---|
| Open | $17.73 | P/E Ratio | 34.54 |
| Prev. Close | $18.12 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $17.53 - $18.12 | Volume | 1,707,535 |
| 52-Wk Range | $15.50 - $25.77 | Avg. Daily Vol. | 1,908,552 |
The best Bull and Bear pitches based on recency and number of recommendations.
From Fidelity or Zacks November 2021:Revenue Growth (Last 5 Years) = 92.7%Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%Price/Sales (TTM) = 5.2
This sector is a scary one! Fear, though, is a fools game. I don't expect this stock to move upwards in the very near future. The cash burn is, well, similar to that Texas A&M bonfire tradition.
Read the most recent pitches from players about EXEL.
Recs
Car12703
(< 20)
Submitted: 11/10/2021 6:26:58 AM :
Start Price:
$18.41
NASDAQ:EXEL Score:
-1.45
From Fidelity or Zacks November 2021:
Revenue Growth (Last 5 Years) = 92.7%
Revenue % Change (Last Qrtr VS. Same Qrtr Prior Year) = 42.1%
Price/Sales (TTM) = 5.2
Recs
MrUrban
(< 20)
Submitted: 7/24/2020 8:04:22 PM :
Start Price:
$24.73
NASDAQ:EXEL Score:
-71.26
First one i picked all by myself, reason:
1. Mkt Cap 7.39B plenty place to grow
2. EPS nxt Yr 94.84%
3.EPS nxt 5Yr 46.00%
4. Sales past 5Yr 107.60%
5. Dept/ Equity 0
Issues:
1. High insider transactions almost 30%
2. Company works on cure for cancer - high volatility
3. EPS this Y -53.80% but justified by Covid-19
Practice and enjoy!
Recs
TMFAdriaCimino
(< 20)
Submitted: 6/26/2020 9:09:05 AM :
Start Price:
$23.50
NASDAQ:EXEL Score:
-75.00
The company's lead molecule, cabozantinib, has the potential for four new indications in the next year or so. And revenue is already climbing at Exelixis thanks to this molecule for kidney and liver cancers.
Find the members with the highest scoring picks in EXEL.
beave35 (86.42) Score: +1,169.53
The Score Leader is the player with the highest score across all their picks in EXEL.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| Playa14 | < 20 |
|
|
5Y | $1.27 | +1,325.98% | +123.10% | +1,202.88 | 0 Comment | |
| beave35 | 86.42 | 12/23/2014 |
|
5Y | $1.30 | +1,292.97% | +123.44% | +1,169.53 | 0 Comment | |
| tomkao | < 20 | 12/15/2014 |
|
5Y | $1.40 | +1,193.57% | +130.55% | +1,063.02 | 0 Comment | |
| jack0071 | 69.54 | 12/3/2014 |
|
5Y | $1.43 | +1,166.43% | +124.19% | +1,042.25 | 0 Comment | |
| portefeuille | 97.79 |
|
|
NS | $1.44 | +1,157.64% | +130.09% | +1,027.55 | 0 Comment | |
| akoniec | < 20 | 10/9/2014 |
|
3Y | $1.55 | +1,068.39% | +136.71% | +931.67 | 0 Comment | |
| dcoyne13 | 46.14 | 9/16/2014 |
|
5Y | $1.62 | +1,017.83% | +132.49% | +885.35 | 0 Comment | |
| foolerhoff | 77.39 | 1/6/2015 |
|
5Y | $1.64 | +1,004.27% | +129.97% | +874.30 | 0 Comment | |
| garisonmp3z | < 20 | 1/5/2015 |
|
5Y | $1.67 | +984.43% | +127.62% | +856.81 | 0 Comment | |
| new2fool23 | 51.33 | 1/5/2015 |
|
1Y | $1.67 | +984.43% | +127.62% | +856.81 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
